TransGenex Nanobiotech, Inc. (TGN), is a Florida-based nanobiotechnology company incorporated in 2004.

Our Mission is to discover, develop and commercialize nano-scale technologies for novel, cost-effective diagnostic and therapeutic agents against cancers and other inflammatory diseases.

Contact Us

Latest News

June 18, 2015

Florida Institute Funds Tampa-based TransGenex Nanobiotech, Inc.



The Florida Institute for the Commercialization of Public Research

October 14, 2014

Transgenex co-founder Dr. Subhra Mohapatra receives USF’s Excellence in Innovation Award.

USF Research News

September 16, 2014

TransGenex Receives $224,999in SBIR Phase-I Contract from National Cancer Institute to further develop and commercialize a biopsy-derived tumoroid platform for personalizing cancer treatment.

TransGenex Receives a second $224,999in SBIR Phase-I Contract from National Cancer Institute to develop new drugs targeting cancer stem cells.

July, 2014

Shyam Mohapatra elected one of six inaugural inductees to Florida Inventors Hall of Fame


Anti-Cancer Drug Discovery


Personalized Cancer Therapy
3D Tumor